This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors. Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.
EVOMELA® Launched in China

- **Only** approved melphalan product in China market
- HDT+ASCT is 1st line treatment for multiple myeloma even in new agent era
- Provides best choice of preparative regimen
  - Lack of propylene glycol solvent (related to certain adverse events)
- Stable and significantly improves handling for physicians
  - Captisol formulation allows for increased stability when reconstituted for patient administration
- As condition to NMPA approval, CASI will implement post- market study after market launch
- Launched in August 2019
Recent Execution in Hematology Oncology Portfolio

Launched in China for multiple myeloma transplant setting in August 2019

Acquired worldwide rights to commercialize anti-CD19 T-cell therapy in June 2019 – targeting acute lymphoblastic leukemia and non-hodgkin’s lymphoma

In-licensed exclusive worldwide rights to novel anti-CD38 monoclonal antibody program in April 2019 – targeting multiple myeloma

NMPA approved MARQIBO® for Clinical Trial of Investigation in April 2019

NMPA approved ZEVALIN® for Clinical Trial of Investigation in March 2019
CNCT-19 (Anti-CD19 T-Cell Therapy)

- Targets CD19, a B-cell surface protein widely expressed during all phases of B-cell development and validated target for B-cell derived hematological malignancies
- CD19-targeted CAR have demonstrated consistently high antitumor efficacy in children and adults with relapsed B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and B-cell non-Hodgkin lymphoma (B-NHL)
- CD19 antigen is the most frequently used biomarker in CAR-T cell therapy clinical trials for hematological malignancies
- CASI has exclusive China and worldwide commercial rights
CID-103 (Potential Best in Class Anti-CD38 mAb)

- Fully human IgG1 anti-CD38 monoclonal antibody recognizing a unique epitope; engineered to have strong ADCC activity against CD38 malignant cells and to reduce CDC activity with a potential reduction of infusion reactions with observed with existing anti-CD38 treatments
- Encouraging preclinical efficacy & safety profile compared to other anti-CD38 mAbs
- Demonstrates greater ADCC activity over Daratumumab and other anti-CD38 mAbs
- In vivo activity outperforms Daratumumab and other anti-CD38 mAbs
- Survival improvement observed in Daudi, Ramos and Raji Xenograft models
- Worldwide license and commercial rights
- CID-103 is at IND/IMPD submission stage of development; phase I study targeted for early 2020
ZEVALIN® and MARQIBO® Clinical Trial Application Approval in China

- CD20-directed radiotherapeutic antibody indicated for treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma (FNHL) and patients with previously untreated follicular non-Hodgkin’s Lymphoma who achieve partial or complete response to first-line chemotherapy
- ZEVALIN® is approved and commercialized in the U.S. by our partner, CASI has exclusive greater China rights

- Novel, sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate, a microtubule inhibitor indicated for the treatment of \( \text{Ph}^{neg} \) acute lymphoblastic leukemia
- MARQIBO® is approved and commercialized in the US by our partner. CASI has exclusive greater China rights
Global Executive Team

Wei-Wu He, PhD
Chairman, CEO
- 25 years of experience in biotech investment
- Founder of Emerging Technology Partners, LLC
- Founder/investor of more than 60 biotech firms
- Venture partner of IDG Capital

Larry Zhang
China President
- Vice President of Novartis (China)
- CEO of Sandoz Pharmaceuticals (China)
- Leadership roles at Bayer Asia Pacific Region and Greater China Region
- Leadership role at Baxter Asia Pacific Region and Greater China Region

Alexander Zukiwski,
MD
CMO
- 23 years of experience in global drug development
- CEO & CMO of Arno Therapeutics
- CMO and Exec. VP of Clinical Research at MedImmune
- Oncology Clinical Development Head of J&J

James Goldschmidt,
PhD
SVP, BD
- More than 25 years of commercial and business development experience
- COO at Macrophage Therapeutics
- VP of ImmuneXcite
- VP of Business Development at TetraLogic Pharmaceuticals

George Chi, CPA
CFO
- Vice President of Finance at Flavors Holdings
- CFO at BPL Plasma
- Finance Director at Unilever

Thomas Zhang China
Commercial GM
- National Operation & Effectiveness Director of Roche Pharmaceuticals in China
- Sales Director of Roche Pharmaceuticals in China
- Sales Manager and Commercial Manager at J&J Pharmaceuticals in China
Commercial Team for Launch of EVOMELA®

- 21 managerial and upper employees in commercial organization, all with more than 10 years experiences at large international pharmaceutical companies
- 90% of employees in commercial operations have prior experience in hematology oncology products
- Cover all CBMTR (China bone marrow transplantation research group) centers with 26 provinces and 105 BMT Centers (hospitals)
- Cooperation with CBMTR to track all HCT cases
R&D and Manufacturing Center in Wuxi

- State-of-art GMP facility currently in design and planning stage
- Approximately 17.6 acres of land located in major biotech and pharmaceutical region
- Over 100,000 square meters of building area
- Convenient transportation to 2 airports, high speed train station and highways
CASi Key Highlights

• Launched EVOMELA® (melphalan for injection), the only commercially available melphalan in China

• Robust pipeline in hematology oncology
  • CID-103 (potential best in class anti-CD38 mAb)
  • CNCT-19 (anti-CD19 T-Cell Therapy)
  • ZEVALIN®
  • MARQIBO®

• Led by an international executive team, with strong commercial and clinical/regulatory teams trained at large pharma, 100+ employees

• State of art GMP manufacturing facility currently in design stage

• Active pursuit of business development opportunities

• Strong cash balance, runway and supported by committed long-term investors
THANK YOU

NASDAQ: CASI
www.casipharmaceuticals.com